Table 2.
Adverse events reported at the 1-year follow-up examination
| Abatacept (n = 43) | Rituximab (n = 46) | TNFi (n = 50) | Total (n = 139) | |||||
|---|---|---|---|---|---|---|---|---|
| Number of events | Number of patients | Number of events | Number of patients | Number of events | Number of patients | Number of events | Number of patients | |
| Cardiovascular event | 1 | 1 | 2 | 2 | 2 | 2 | 5 | 5 |
| Infection | 9 | 6 | 5 | 4 | 11 | 7 | 25 | 18 |
| Malignancy | 0 | 0 | 3 | 3 | 0 | 0 | 3 | 3 |
| Laboratory abnormalitiesa | 1 | 1 | 0 | 0 | 2 | 2 | 3 | 3 |
| Skin condition | 3 | 3 | 3 | 3 | 6 | 5 | 12 | 11 |
| Gastroenterological | 2 | 2 | 3 | 3 | 0 | 0 | 5 | 5 |
| Otherb | 5 | 4 | 7 | 5 | 7 | 4 | 19 | 13 |
| Total | 21 | 16 | 23 | 15 | 28 | 20 | 78 | 51 |
aLiver function test elevations and leukopenia. bIn this group, the adverse effects consisted primarily of influenza, fever, fatigue, headache and/or dizziness. One patient in the abatacept group developed psychosis 4 months after the start of the study.